James Raybourn, MD
Urology · Greenwood, INNPI 1871736595
Payments from drug & device makers
What this record shows
This record is dominated by other: $22,071 of the $27,495 with a category attached, or 80.3%. Central Indiana URS Consumables, LLC accounts for 80.3% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2024 at $16,532 and has fallen 51.0% since, to $8,098 in 2025.
Across 238 payments — averaging $115.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Central Indiana URS Consumables, LLC$22K
- Bayer$818
- Johnson & Johnson$641
- Dendreon Pharmaceuticals LLC$533
- Pfizer$427
- Astellas Pharma US Inc$377
- plus $3K from 35 others
Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Central Indiana URS Consumables, LLC$16K
What the payments were for
- Food & beverage$5,17019%
- Education$2531%
- Other$22,07180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Central Indiana URS Consumables, LLC | 4 | $22,071 |
| Bayer | 25 | $818 |
| Johnson & Johnson | 35 | $641 |
| Dendreon Pharmaceuticals LLC | 18 | $533 |
| Pfizer | 25 | $427 |
| Astellas Pharma US Inc | 13 | $377 |
| Accord Healthcare, Inc. | 14 | $280 |
| Sumitomo Pharma America, Inc. | 8 | $259 |
| Sanofi | 8 | $179 |
| AstraZeneca | 9 | $172 |
| Sun Pharmaceutical Industries Inc. | 8 | $170 |
| Myovant Sciences Inc. | 5 | $133 |
| Tolmar, Inc. | 5 | $124 |
| Amgen | 6 | $120 |
| AbbVie | 6 | $118 |
| Novartis | 4 | $113 |
| Merck | 5 | $101 |
| Blue Earth Diagnostics | 5 | $99 |
| Progenics Pharmaceuticals, Inc. | 4 | $97 |
| Urogen Pharma, Inc. | 4 | $95 |
| Laborie Medical Technologies Corp. | 2 | $62 |
| Rochester Medical Corporation | 1 | $48 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $47 |
| Ferring Pharmaceuticals Inc. | 3 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Davol Inc. | 2 | $35 |
| Coloplast | 2 | $34 |
| Civco Medical Instruments | 1 | $29 |
| BD | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Medtronic | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Cook Medical LLC | 1 | $16 |
| Vertex | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
| Sanara Medtech Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Clinigen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dornier MedTech$88,286
- CVAC Aspiration System$22,071
- Xofigo$353
- PROVENGE$139
- Nubeqa$120
How this compares
$27,495 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 141 | $1,969,907 |
| XtandiEnzalutamide | 111 | $1,184,608 |
| OrgovyxRelugolix | 158 | $409,885 |
| NubeqaDarolutamide | 32 | $344,321 |
| LynparzaOlaparib | 26 | $236,930 |
| Abiraterone Acetate | 198 | $180,144 |
| MyrbetriqMirabegron | 141 | $103,447 |
| GemtesaVibegron | 72 | $73,140 |
| Mirabegron ErMirabegron | 16 | $12,849 |
| Tamsulosin Hcl | 524 | $9,622 |
| Solifenacin Succinate | 90 | $4,352 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 279 | $4,150 |
| Finasteride | 322 | $3,776 |
| Silodosin | 28 | $2,519 |
| Methenamine Hippurate | 51 | $2,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $641 | $1,969,907141 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $377 | $1,288,054252 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $259 | $483,024230 claims |
| BayerNubeqa | $818 | $344,32132 claims |
| AstraZenecaLynparza | $172 | $236,93026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.
Other urology in Greenwood
- Eugene ConeGreenwood$114K
- Brian OrrGreenwood$50K
- David GilleyGreenwood$31K
- Bradley OrrisGreenwood$29K
- Weston KitleyGreenwood$24K
- Charles SchwabGreenwood$23K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.